VIDEO: Ocuphire’s innovations range from mydriasis reversal to oral treatment for DR
Click Here to Manage Email Alerts
Key takeaways:
- Ocuphire Pharma is developing two products.
- Nyxol inhibits the action of the iris dilator muscle.
- APX3330 is for nonproliferative and early proliferative diabetic retinopathy.
SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Jay S. Pepose, MD, PhD, presents two products currently in development by Ocuphire Pharma, one for the front and one for the back of the eye.
On the refractive side, Nyxol is an alpha-1 inhibitor that inhibits the action of the iris dilator muscle and is being developed for reversal of pharmacological mydriasis, presbyopia and night vision disturbances.
The other product is APX3330, an oral treatment for moderate to severe nonproliferative and early proliferative diabetic retinopathy. At these stages of DR, the approach is normally watch and wait, and “an oral agent that can treat these patients and prevent progression would be a really welcome element to our armamentarium,” Pepose said.
A phase 2 trial showed a statistical difference between treated vs. control patients.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts